-- 米国エネルギー省は木曜日、戦略石油備蓄(SPR)から最大9250万バレルの原油を緊急交換するための提案依頼書(RFP)を4度目として発行した。これは、国際エネルギー機関(IEA)による4億バレルの協調行動のうち、1億7200万バレルを放出するという公約を履行するものである。 この4件のRFPは、原油の市場への迅速な供給を確保するだけでなく、返還時に24%のプレミアム(追加バレル)を保証するものでもある。最初の3件の緊急交換RFPでは、約8000万バレルの原油が供給された。 エネルギー省によると、中東紛争による供給途絶を受けて実施されたこの一連のSPR交換要請は、過去50年間で最速かつ最大規模のものとなった。 今回の原油交換では、バイユー・チョクトー、ブライアン・マウンド、ビッグ・ヒル、ウェスト・ハックベリーの各SPR貯蔵施設から原油が供給される。 「エネルギー省(DOE)の交換権限に基づき、参加企業は借り入れた9250万バレルの原油をプレミアム原油で返却し、戦略石油備蓄(SPR)が現在の水準を上回るとともに、製油所と世界の石油市場に即時供給することを保証する」とDOEは述べた。 SPR交換の募集は、中部標準時(CT)5月4日午前11時まで受け付けている。
Related Articles
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.